A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers

Neoplasia

Volumn 7, Issue 5, 2005, Pages 509-521

  Halder, Sunil K ^a   Beauchamp, R Daniel ^a   Datta, Pran K ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EMT VEGF; Invasion; Metastasis; SB 431542; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR PROMOTION;

EID: 20344385003     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04640     Document Type: Article

References (31)

1. Blake JF (2000). Chemoinformatics-predicting the physicochemical properties of 'drug-like' molecules. Curr Opin Biotechnol 11, 104-107.
2. Heldin CH, Miyazono K, and ten Dijke P (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
3. Massague J (1998). TGF-beta signal transduction. Annu Rev Biochem 67, 753-791.
4. Attisano L and Wrana JL (2000). Smads as transcriptional co-modulators. Curr Opin Cell Biol 12, 235-243.
5. Massague J and Wotton D (2000). Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19, 1745-1754.
6. Kawabata M and Miyazono K (1999). Signal transduction of the TGF-beta superfamily by Smad proteins. J Biochem (Tokyo) 125, 9-16.
7. Wrana JL (2000). Crossing Smads. Sci STKE 2000, RE1.
8. de Caestecker MP, Piek E, and Roberts AB (2000). Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92, 1388-1402.
9. Siegel PM and Massague J (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3, 807-821.
10. Wakefield LM and Roberts AB (2002). TGF-beta signaling: positive and negative effects on tumorigenesis, Curr Opin Genet Dev 12, 22-29.
11. Dumont N and Arteaga CL (2003). Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3, 531-536.
12. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, et al. (2002). Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109, 1607-1615.
13. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al. (2002). Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109, 1551-1559.
14. Callahan JF, Burgess JL, Fomwald JA, Gaster LM, Harling JD, Harrington J, Heer J, Kwon C, Lehr R, Mathur A, et al. (2002). Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 45, 999-1001.
15. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, and Hill CS (2002). SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62, 65-74.
16. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Marling J, et al. (2002). Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62, 58-64.
17. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RD, and Beauchamp RD (2000). Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 275, 6628-6635.
18. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, and Moses HL (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12, 27-36.
19. Moses HL, Tucker RF, Leof EB, Coffey RJ, Halper J, and Shipley GD (1985). Type beta transforming growth factor is a growth stimulator and a growth inhibitor. In Growth factors and Transformation. Cancer Cells 3. J. Feramisco, B. Ozanne, and C. Stiles, eds. (New York: Cold Spring Harbor Press), 65-71.
20. Lim IK, Joo HJ, Choi KS, Sueoka E, Lee MS, Ryu MS, and Fujiki H (1997). Protection of 5alpha-dihydrotestosterone against TGF-beta-induced apoptosis in FaO cells and induction of mitosis in HepG2 cells. Int J Cancer 72, 351-355.
21. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, and Gress TM (2001). Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61, 4222-4228.
22. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, et al. (1999). Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1, 260-266.
23. Postlethwaite AE, Keski-Oja J, Moses HL, and Kang AH (1987). Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med 165, 251-256.
24. Bakin AV, Rinehart C, Tomlinson AK, and Arteaga CL (2002). p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115, 3193-3206.
25. Derynck R, Akhurst RJ, and Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29, 117-129.
26. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, and Rich JN (2004). SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3, 737-745.
27. Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, et al. (2003). SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 63, 7791-7798.
28. Oft M, Heider KH, and Beug H (1998). TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8, 1243-1252.
29. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, and Takahashi T (2001). Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61, 8331-8339.
30. Watabe T, Nishihara A, Mishima K, Yamashita J, Shimizu K, Miyazawa K, Nishikawa S, and Miyazono K (2003). TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 163, 1303-1311.
31. Kinzler KW and Vogelstein B (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.